Search

Olga Khorkova Sherman

from Great Barrington, MA
Age ~63
Get Report
Also known as:
Olga E Khorkova, Olga E Sherman, Olga K Sherman, Olga N
Related to:
Brett A Sherman, 57Gerald Sherman, 75Bernard ShermanJoanne Cameron ShermanJoanne C Sherman, 65Adele Sherman, 97Richard L Sherman, 67Steven M Sherman, 69
Connected to:
Addie L Sherman, 97Alandra Sherman, 39Allie Sherman, 32Alvie D Sherman, 108Andrea Sherman, 47Andrew Sherman, 44Angelica Sherman, 34Arissa A Sherman, 40Arkadiy S Sherman, 60Arvie L Sherman, 84

Olga Sherman Phones & Addresses

  • Great Barrington, MA
  • 18288 SE Heritage Dr, Jupiter, FL 33469 (561) 575-5737
  • Tequesta, FL
  • 570 Manchester Ave, North Haledon, NJ 07508 (973) 636-6610
  • Cherry Hill, NJ
  • New Brunswick, NJ
  • Bridgewater, NJ
  • Somerset, NJ
  • Marianna, FL
  • River Vale, NJ
  • Brooklyn, NY

Professional Records

License Records

Olga Sherman

License #:
RS047934A - Expired
Category:
Real Estate Commission
Type:
Real Estate Salesperson-Standard

Business Records

Name / Title
Company / Classification
Phones & Addresses
Olga Khorkova Sherman
Manager
First Greenwich Capital LLC
General Equipment Leasing
601 Heritage Dr, Jupiter, FL 33458
Olga Sherman
Clinical Specialist
Va Medical Center
Medical Doctor's Office
130 W Kingsbridge Rd, Bronx, NY 10468
Olga Sherman
8507 MORE CLEANERS, INC
Hippodrome Services Corp 85-07 Northern Blvd, Jackson Heights, NY 11372
63-69 Douglaston Pkwy, Little Neck, NY 11362
Olga Sherman
Chief Executive Officer
HIPPODROME DRY CLEANING, INC
Drycleaning Plant
1120 Ave Of Americas, New York, NY 10036
1120 Ave Of The Americas, New York, NY 10036
(212) 768-9080
Olga Sherman
Clinical Specialist
Veterans Health Administration
Medical Center · Medical Doctor's Office Administrative Veterans' Affairs · Network Office · Administrative Veterans' Affairs
130 W Kingsbridge Rd, Bronx, NY 10468
(718) 584-9000, (718) 741-4110, (718) 741-4438, (718) 562-9120

Publications

Us Patents

Treatment Of Hemoglobin (Hbf/Hbg) Related Diseases By Inhibition Of Natural Antisense Transcript To Hbf/Hbg

View page
US Patent:
8318690, Nov 27, 2012
Filed:
Apr 30, 2010
Appl. No.:
12/770847
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Carlos Coito - West Palm Beach FL, US
Assignee:
CuRNA, Inc. - Miami FL
International Classification:
C12N 15/11
US Classification:
514 44A
Abstract:
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hemoglobin (HBF/HBG), in particular, by targeting natural antisense polynucleotides of Hemoglobin (HBF/HBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HBF/HBG.

Treatment Of Sirtuin 1 (Sirt1) Related Diseases By Inhibition Of Natural Antisense Transcript To Sirtuin 1

View page
US Patent:
20110237649, Sep 29, 2011
Filed:
Dec 2, 2009
Appl. No.:
13/132987
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Carlos Coito - West Palm Beach FL, US
Belinda De Leon - West Palm Beach FL, US
Assignee:
OPKO CuRNA, LLC - Miami FL
International Classification:
A61K 31/711
C12N 5/071
C07H 21/04
C07H 21/02
A61K 31/7105
G01N 33/48
A61P 35/00
A61P 31/18
A61P 9/10
A61P 25/16
A61P 25/28
A61P 35/02
A61P 3/10
A61P 1/00
A61P 17/00
A61P 25/02
A61P 3/04
A61P 13/00
US Classification:
514 44 A, 435375, 536 245, 536 231, 514 44 R, 436 94
Abstract:
Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.

Treatment Of Vascular Endothelial Growth Factor (Vegf) Related Diseases By Inhibition Of Natural Antisense Transcript To Vegf

View page
US Patent:
20110237650, Sep 29, 2011
Filed:
Dec 2, 2009
Appl. No.:
13/132997
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Assignee:
OPKO CURNA, LLC - Miami FL
International Classification:
A61K 31/7088
C12N 5/071
C07H 21/00
A61K 31/7115
A61K 31/712
A61K 31/7125
A61K 31/713
G01N 33/53
A61P 35/00
A61P 9/00
A61P 9/04
A61P 31/00
A61P 37/06
A61P 29/00
A61P 9/10
A61P 3/04
A61P 17/06
A61P 17/00
A61P 13/12
A61P 27/02
A61P 11/06
A61P 1/00
A61P 25/00
A61P 25/28
A61P 25/16
A61P 1/02
A61P 15/00
A61P 19/02
A61P 19/08
A61P 43/00
US Classification:
514 44 A, 435375, 536 245, 536 235, 436501
Abstract:
Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.

Treatment Of Tumor Suppressor Gene Related Diseases By Inhibition Of Natural Antisense Transcript To The Gene

View page
US Patent:
20110294870, Dec 1, 2011
Filed:
Dec 3, 2009
Appl. No.:
13/133039
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Assignee:
OPKO CuRNA, LLC - Miami FL
International Classification:
A61K 31/7088
C07H 21/00
G01N 25/04
A61K 31/712
A61K 31/7125
A61K 31/7115
A61K 31/713
C07H 21/04
A61P 35/00
A61P 37/06
A61P 35/02
A61P 37/00
A61P 43/00
A61P 25/28
A61P 25/00
A61P 25/16
A61P 29/00
A61P 9/00
A61P 9/10
A61P 19/10
A61P 7/00
A61P 31/12
A61P 17/02
A61P 3/10
A61P 3/00
A61P 13/12
A61P 9/04
C12N 5/09
US Classification:
514 44 A, 435375, 536 245, 436501
Abstract:
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.

Treatment Of Sirtuin 1 (Sirt1) Related Diseases By Inhibition Of Natural Antisense Transcript To Sirt1

View page
US Patent:
20110319317, Dec 29, 2011
Filed:
Mar 3, 2010
Appl. No.:
13/254600
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Carlos Coito - West Palm Beach FL, US
Belinda De Leon - San Francisco CA, US
Assignee:
OPKO CuRNA, LLC - Miami FL
International Classification:
A61K 31/713
A61P 35/00
A61P 25/28
A61P 25/14
A61P 25/16
A61P 25/00
A61P 21/00
A61P 3/00
A61P 5/50
A61P 3/10
A61P 3/04
A61P 3/08
A61P 7/00
A61P 3/06
A61P 19/10
A61P 35/02
A61P 1/16
A61P 25/32
A61P 31/14
A61P 27/02
A61P 9/10
A61P 9/04
A61P 1/04
A61P 29/00
A61P 1/00
A61P 19/04
A61P 19/02
A61P 11/00
A61Q 19/08
A61P 13/00
A61P 17/00
C12N 5/071
C12Q 1/68
C07H 21/02
US Classification:
514 16, 514 44 A, 536 245, 514 193, 514 194, 514 195, 514 178, 514 177, 514 179, 514 67, 514 69, 514 48, 514 68, 514 74, 514 169, 514 196, 514 43, 514 208, 514 19, 514 164, 514 132, 514 166, 514 168, 514 188, 514 186, 435375, 435 612
Abstract:
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.

Treatment Of Brain Derived Neurotrophic Factor (Bdnf) Related Diseases By Inhibition Of Natural Antisense Transcript To Bdnf

View page
US Patent:
20110319475, Dec 29, 2011
Filed:
Feb 12, 2010
Appl. No.:
13/201254
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Carlos Coito - West Palm Beach FL, US
Assignee:
OPKO CuRNA, LLC - Miami FL
International Classification:
A61K 31/7088
C07H 21/04
A61P 25/28
A61P 25/16
A61P 25/24
A61P 25/18
A61P 25/22
A61P 25/30
A61P 29/00
A61P 3/04
A61P 35/00
A61P 11/06
C12N 5/071
G01N 33/53
C12Q 1/68
C07H 21/00
US Classification:
514 44 A, 536 261, 536 245, 435375, 436501, 435 612
Abstract:
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

Treatment Of Glial Cell Derived Neurotrophic Factor (Gdnf) Related Diseases By Inhibition Of Natural Antisense Transcript To Gdnf

View page
US Patent:
20110319476, Dec 29, 2011
Filed:
Feb 12, 2010
Appl. No.:
13/201260
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Carlos Coito - West Palm Beach FL, US
International Classification:
A61K 31/713
A61P 25/00
A61P 25/28
A61P 25/16
A61P 25/14
A61P 25/24
A61P 25/18
A61P 25/22
A61P 3/00
A61P 25/30
A61P 27/02
A61P 27/16
A61P 25/08
A61P 9/10
A61P 3/10
A61P 13/12
A61P 25/02
A61P 3/04
A61P 35/00
A61P 17/00
A61P 1/00
A61P 1/04
A61P 17/02
A61P 21/00
A61P 7/06
A61P 7/00
A61P 37/00
A61P 31/18
A61P 31/12
C12N 5/071
G01N 25/04
C12Q 1/68
C07H 21/02
US Classification:
514 44 A, 536 245, 435375, 436501, 435 612
Abstract:
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

Treatment Of Nuclear Factor (Erythroid-Derived 2)-Like 2 (Nrf2) Related Diseases By Inhibition Of Natural Antisense Transcript To Nrf2

View page
US Patent:
20120004184, Jan 5, 2012
Filed:
Mar 16, 2010
Appl. No.:
13/256720
Inventors:
Joseph Collard - Delray Beach FL, US
Olga Khorkova Sherman - Tequesta FL, US
Carlos Coito - West Palm Beach FL, US
International Classification:
A61K 31/7088
A61K 31/712
A61K 31/7125
A61K 31/713
C07H 21/02
C07H 21/00
C07H 21/04
A61K 38/02
C07K 2/00
A61P 35/00
A61P 29/00
A61P 9/10
A61P 25/00
A61P 21/00
A61P 1/00
A61P 1/16
A61P 27/02
A61P 11/06
A61P 17/00
A61P 3/10
A61P 37/06
A61P 37/04
A61P 11/00
C12N 5/00
US Classification:
514 209, 435375, 514 44 A, 536 245, 530395
Abstract:
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nu-clear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
Control profile
Olga Khorkova Sherman from Great Barrington, MA, age ~63 Get Report